Cover Image

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Abstract Background BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adhe...

Full description

Saved in:
Bibliographic Details
Main Authors: S. E. J. van de Berg (Author), P. T. Pelzer (Author), A. J. van der Land (Author), E. Abdrakhmanova (Author), A. Muhammad Ozi (Author), M. Arias (Author), S. Cook-Scalise (Author), G. Dravniece (Author), A. Gebhard (Author), S. Juneja (Author), R. Handayani (Author), D. Kappel (Author), M. Kimerling (Author), I. Koppelaar (Author), S. Malhotra (Author), B. Myrzaliev (Author), B. Nsa (Author), J. Sugiharto (Author), N. Engel (Author), C. Mulder (Author), S. van den Hof (Author)
Format: Book
Published: BMC, 2021-07-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items